More patients will soon be asking about male birth control. Are you ready for these clinic conversations?

After years of stalled progress, male contraception is no longer a purely theoretical conversation. Several products are in mid- to late-stage development, some with a plausible path to consumers within the next few years.

More striking still: Men are actively lining up for trials, emailing researchers, and asking to be put on waitlists. This is not the apathy many clinicians were taught to expect. ^[]

What’s actually new—and how close are we?

The current pipeline is more robust than it’s ever been, with three contenders drawing the most attention:

• NES/T (Nestorone/testosterone) gel: A daily transdermal hormonal gel that suppresses sperm production. ^[] It has completed Phase 2 trials. ^[] Think of it as a male analogue to combined hormonal contraception—it’s effective and reversible but requires adherence and counseling around hormone exposure to partners.

• YCT-529: A nonhormonal oral pill that interferes with sperm production. ^[] It’s currently in a Phase 2a study, and early signals show reduced sperm counts. The “nonhormonal pill” framing matters here; it’s resonating strongly with men wary of mood or libido effects.

• ADAM (Contraline): An implanted hydrogel that blocks sperm transport—essentially a temporary vasectomy. ^[] It’s currently in a first-in-human clinical trial and has demonstrated sperm suppression for at least 24 months. Because it may be regulated as a device rather than a drug, its path to market could be faster than oral or hormonal options.

None of these are on pharmacy shelves yet. But for the first time, “a few years away” doesn’t sound like wishful thinking.

Men actually want this

The longstanding assumption that men won’t reliably use contraception and women won’t trust them to no longer holds up well against the data.

Researchers running trials say the interest is unmistakable. ^[] Men are reaching out from across the US, France, Germany, Kenya, and beyond, often without being prompted. Trial recruitment, once a major concern, has become almost the opposite problem.

“Men want this. We are receiving emails from men all over the world asking to participate,” Nadja Mannowetz, the co-founder and chief science officer of YourChoice, the San Francisco–based biopharma startup that is conducting trials for YCT-529, told STAT News.^[]

And this isn’t limited to one demographic. Men expressing interest include:

• Younger patients trying to avoid derailing their education or early careers

• Older men who feel “done” with childbearing but aren’t ready for permanent sterilization

• Men who’ve seen partners struggle with side effects from hormonal contraception or IUDs

• Men motivated by reproductive autonomy in a post-Dobbs landscape

What comes through repeatedly is not reluctance, but relief—at the idea of finally having agency.

Side effects: A different tolerance threshold

Clinicians may remember the 2016 trial of an injectable male contraceptive that was halted due to side effects like acne and mood changes. ^{[] []}

That doesn’t mean safety standards should change—but it does suggest that older assumptions about male intolerance for side effects may be outdated.

What this means in the exam room

Fielding patient questions around male birth control may not yet be common practice, many of them are indeed thinking about it. If the subject of contraception comes up in the exam room, clinicians may start hearing questions like:

• "Are there any options outside of vasectomy?”

• “How soon could the options be available to me?”

• “Would you trust it?”

For now, the honest answer is that we don't have anything FDA-approved for male partners, but the pipeline is real and interest is high. Clinicians who recognize that shift—and engage patients with curiosity rather than skepticism—will be better positioned when male contraception finally moves from trials to practice.